U: The Mind Company is best understood as a consumer tPRNS wellness device positioned below regulated therapeutic devices like Flow Neuroscience's FDA-approved tDCS. Its institutional research claims are difficult to independently verify, and the $350 price point and pre-seed stage suggest a direct-to-consumer lifestyle product with long-term clinical ambitions but no near-term regulatory pathway.